All In Biotech

Drug Trial Radar · NCT03913923

Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma

International Multicenter Double-Blind Placebo-Controlled Comparative Randomized Trial of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) And BCD-100 (Anti-PD-1) Therapy Compared to BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma

Last checked: Nov 19, 2026Latest source record: Feb 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 117 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

117

Actual

Start

Jul 1, 2019

Primary completion

Jul 2023

Study completion Dec 2023

Sponsor

Lead sponsor
BiocadIndustry
Sponsor type
Industry
First posted
Apr 12, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter randomized double-blind placebo-controlled phase II clinical trial. The purpose of this trial is to evaluate efficacy and safety of therapy consisting of BCD-217 (fixed dose combination of anti-CTLA-4 and anti-PD-1 monoclonal antibodies) and sequential BCD-100 (anti-PD-1 monoclonal antibody) versus BCD-100 monotherapy as first-line treatment in patients with treatment-naïve unresectable or metastatic melanoma.

Conditions

  • Melanoma
  • Melanoma Metastatic

Interventions

  • BCD-217Biological

    Combination of anti-CTLA-4 and anti-PD-1 monoclonal antibodies, 1mg/kg and 3 mg/mg, respectively, given Q3W as IV infusion for first 4 blinded infusions

  • BCD-100Biological

    Anti-PD-1 monoclonal antibody, 3 mg/kg, given Q3W as IV infusion for first 4 blinded infusions, after - 1 mg/kg, given Q2W as IV infusion

  • PlaceboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Median Progression-Free SurvivalTime frame: 2 years

Locations

23 sites in 2 countries. Site status is shown where the registry gives one.

  • Healthcare Institution "Minsk Municipal Clinical Oncolo-gy Dispensary" (MMCOD)

    Minsk, Belarus

  • State Institution "N.N. Aleksandrov Republican Research and Practical Center for Oncology and Medical Radiology"

    The Settlement of Lesnoy, Minsk District, Belarus

  • State Budgetary Healthcare Institution of the Ar-khangelsk Region "Arkhangelsk Clinical Oncology Dispensary"

    Arkhangelsk, Russia

  • Territorial State Budgetary Healthcare Institution "Altai Territorial Clinical Oncology Dispensary"

    Barnaul, Russia

  • State Budgetary Healthcare Institution "Chelyabinsk Regional Clinical Center for Oncology and Nuclear Medicine",

    Chelyabinsk, Russia

  • State public health institution "Republican Clinical Oncology Dispensary" of the Ministry of Health of the Republic of Tatarstan

    Kazan', Russia

  • Regional State Budgetary of Healthcare Insti-tution "Kostroma Oncology Dispensary"

    Kostroma, Russia

  • Medsi Group of Companies Joint-Stock Company

    Moscow, Russia

  • "Russian Cancer Research Center named after N.N. Blokhin "of the Ministry of Health of the Russian Federation

    Moscow, Russia

  • State Health Care Institution "Moscow City Oncology Hospital № 62" Moscow Health Department

    Moscow, Russia

  • State Budgetary Healthcare Institution of the Novosi-birsk Region "Novosibirsk Regional Clinical Oncolo-gy Dispensary"

    Novosibirsk, Russia

  • State budget healthcare institution Omsk region "Clinical Oncology Dispensary"

    Omsk, Russia

  • JSC "Modern Medical Technologies"

    Saint Petersburg, Russia

  • AV Medical Group Limited Liability Company

    Saint Petersburg, Russia

  • Federal State Institution "N.N. Petrov National Medical Research Center for Oncology"

    Saint Petersburg, Russia

  • Saint-Petersburg Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)

    Saint Petersburg, Russia

  • Federal State Budgetary Educational Institution of Higher Education "St. Petersburg State University"

    Saint Petersburg, Russia

  • State-financed Health Institution "Samara Region Clinical Oncology Dispansary"

    Samara, Russia

  • Clinical Oncologic Dispensary No. 2

    Sochi, Krasnodar Territory, Russia

  • Krasnoyarsk Regional Clinical Oncological Dispensary named after A.I. Kryzhanovsky

    Krasnoyarsk, Krasnoyarsk Krai, Russia

  • Murmansk Regional Clinical Hospital named after P.A. Bayandina

    Murmansk, Murmansk Oblast, Russia

  • LLC "New Clinic"

    Pyatigorsk, Stavropol Kray, Russia

  • Regional Clinical Oncology Hospital

    Yaroslavl, Yaroslavl Oblast, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.